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Abstract Bone marrow transplantation (BMT) and im-
munosuppression (IS) have improved the prognosis of
aplastic anemia; both treatments have specific advantages
and drawbacks but similar survival rates. Analysis of
additional endpoints may help in treatment decisions. In a
single-center study, patients with aplastic anemia treated
with IS (n=155) or BMT (n=52) were compared for
survival, event-free survival, and quality-adjusted time
without symptoms and toxicity (Q-TWiST). Probability of
overall and event-free survival at 15 years was similar
among both groups (BMT 51±15% and 25±14%, IS 53
±10% and 27±8%), with more early deaths in the
transplant group and more late deaths in the IS group.
There were differences in terms of mean duration of seven
analyzed health states: time with symptoms from treat-
ment-related toxicity (IS 0.36 years, BMT 0.27), transfu-
sion dependency (IS 0.66 years, BMT 0.1 years), partial
remission (IS 3.27 years, BMT 1.42), and secondary
clonal disorder (IS 0.68 years, BMT 0.04) was signifi-
cantly longer for IS compared to BMT (p≤0.001). Patients
treated with BMT spent more time with extensive chronic
graft-versus-host disease (GvHD) (IS 0 years, BMT 0.96,
p<0.023) and in CR without drugs (IS 1.22 years, BMT
2.43, p=0.056). In conclusion, survival, event-free survi-
val, and Q-TWiST are similar. BMT-treated patients had
longer periods free from symptoms, while IS-treated
patients needed closer medical care, transfusion support,
and medications.
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Introduction
Severe aplastic anemia is a rare disease characterized by
pancytopenia and bone marrow aplasia. The goal of the
treatment is to improve peripheral blood counts in order to
free the patients of transfusions and the risk of bleeding
and opportunistic infections. Bone marrow transplantation
(BMT) as well as immunosuppression are standard
treatment modalities that have improved the previously
poor prognosis [1–6]. After any of the two treatments,
more than 80% of patients are free from transfusions and
some of them even normalize their cell counts. BMT is the
standard approach for younger patients with an HLA-
matched sibling donor, while immunosuppression is the
treatment of choice for patients not eligible for BMT. In
patients over the age of 40, it is less clear whether they
should receive a BMT or antithymocyte globulin (ATG)
even if they do have a matched sibling donor. With BMT,
the defective organ is replaced by healthy marrow.
Immunosuppressive treatment on the other hand will not
cure the disease. It aims at eliminating “autoaggressive”
cells that are responsible for the aplastic marrow resulting
in pancytopenia. Despite these differences, there is no
clear-cut advantage in terms of overall survival for either
treatment form. Each treatment modality has its advan-
tages and drawbacks [7–12].
Overall survival does not sufficiently describe the
outcomes of patients with aplastic anemia. Therefore,
one might want to take additional endpoints such as event-
free survival, the ability to tolerate treatment, and quality
of life during different sequences of relevant health states
into account in the decision making process, when
different treatment options result in similar long-term
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survival. In aplastic anemia, quality of life outcomes are
affected by treatment toxicity, graft rejection, infections,
and graft-versus-host disease (GvHD) after BMT [13–15],
and by persisting cytopenia due to slow or incomplete
responses, relapse of aplastic anemia, or the development
of clonal disorders such as myelodysplastic syndrome
(MDS) or paroxysmal nocturnal hemoglobinuria (PNH)
after immunosuppression [16–18].
In order to integrate quality of life considerations into
comparing the two treatment modalities, additional factors
such as treatment toxicity, transfusion and drug require-
ment, chronic GvHD, or clonal evolution have to be
considered. The quality-adjusted time without symptoms
and toxicity (Q-TWiST) methodology splits up survival
times into several distinct periods associated with relevant
health states weighted by quality of life factors [19–23].
We compared in a retrospective, single-center study
aplastic anemia patients treated with BMT to those treated
with immunosuppression applying survival, event-free
survival, and Q-TWiST methodology.
Patients and methods
Study population
Patients with aplastic anemia as defined by the criteria of
Bacigalupo and Camitta [24, 25] were treated since 1976
in a prospective single-center study at the University
Hospital of Basel. Patients younger than 40 years of age
with an HLA-matched sibling donor received allogeneic
BMT, older patients and patients without a marrow donor
were treated with ATG-based immunosuppression. On 1
January 1999, 207 patients were included in the study.
Fifty-two underwent marrow transplantation and 155
received ATG. Of the 155 patients receiving ATG as
first-line treatment, 8 were subsequently transplanted.
These eight patients are included in the ATG group.
The characteristics of the patients are shown in Table 1.
Of the 207 patients, 55 fulfilled the criteria of very severe
aplastic anemia, 88 had severe, and 64 patients non-severe
aplastic anemia. Patients with non-severe aplastic anemia
had either thrombocytes <10×109 l−1, or neutrophils
<0.5×109 l−1, or depended on transfusions. Both treatment
groups were comparable for gender, etiology, severity of
the disease, and for blood values before first-line treat-
ment. The median age at first-line treatment was 19 years
(range: 2–55 years) for BMT compared to 23 years (range:
2–74 years) in ATG-treated patients (p=0.039). The
difference in frequency of splenectomy is due to a
protocol of splenectomy in nonresponders to ATG prior
to salvage immunosuppressive retreatment [26]. All
patients were either treated in laminar air flow rooms or
in single rooms with reverse isolation. They all received
standard supportive care, including transfusions of red
blood cells and single-donor platelet concentrates, as well
as application of broad-spectrum intravenous antibiotics in
case of fever or infections. The median duration of
observation since first-line treatment in surviving patients
was similar in both treatment groups, i.e., 11.5 years
(range: 2–22 years) for BMT patients and 11.3 (range:
0.2–22 years) for patients treated with ATG.
Table 1 Characteristics of the
patients with aplastic anemia
treated with bone marrow
transplantation (BMT) or an-
tithymocyte globulin (ATG)
aAccording to Bacigalupo et al.
[24], Camitta et al. [25]
BMT ATG p value
Patients(n) 52 155
Male gender 27 (52%) 85 (55%) 0.418
Age at first treatment
Median age (range) (years) 19 (2–55) 23 (2–74) 0.039
Patients >40 years 3 (6%) 37 (24%) 0.047
Etiology
Idiopathic 42 (81%) 125 (81) 0.828
Viral 3 (6%) 10 (6%)
Toxic/drugs 7 (13%) 18 (12)
Others 0 (0%) 2 (1%)
Severity of aplastic anemiaa
Non-severe 14 (27%) 50 (32%) 0.759
Severe 23 (44%) 65 (42%)
Very severe 15 (29%) 40 (26%)
Median blood values at diagnosis (range)
Neutrophil counts (×109 l−1) 0.45 (0–3.0) 0.46 (0–2.1) 0.536
Platelet counts (×109 l−1) 14 (1–97) 15 (1–218) 0.450
Reticulocyte counts (×109 l−1) 14 (0–77) 18 (0–186) 0.384
MCV (fl) 96 (84–126) 97 (80–133) 0.948
Transfusion dependence 51 (98%) 141 (91%) 0.78
Splenectomy 2 (4%) 84 (54%) <0.001
Median time interval (range)
Diagnosis first-line treatment (months) 1.7 (0.2–14) 1.2 (0.03–378) 0.130
Follow-up (years) 11.5 (2–22) 11.3 (0.2–22) 0.439
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Treatment protocol
The treatment protocol and overall results of the study
have been published previously [27–29]. In short, the ATG
treatment protocol was as follows: from 1976 to 1991
equine antithymocyte globulin from the same manufac-
turer (Lymphoser, Swiss Serum and Vaccine Institute,
Berne, Switzerland) was used in a dose of 40 mg/kg per
day for 4 days. Since 1992 a different equine antithymo-
cyte globulin preparation (Lymphoglobuline), provided by
SangStat (Fremont, Calif., USA), was used in a dose of
15 mg/kg per day for 5 days. Methylprednisolone was
given in a dose of 1 g/day for all patients treated between
1981 and 1992 and in a dose of 2 mg/kg per day thereafter.
Cyclosporine in a dose of 5 mg/kg per day was added to
the regimen in 1991 and continued for at least 1 year.
All patients treated with BMT were conditioned with
cyclophosphamide at a dose of 50 mg/kg per day for 4
days. Twenty-one patients received unirradiated donor
buffy coat after transplantation. Since 1994, ATG was
added at a dose of 30 mg/kg daily for 3 days
(Lymphoglobuline, SangStat, Fremont, Calif., USA). For
prevention of GvHD patients received methotrexate alone
until 1979. Since July 1979, patients were given cyclo-
sporin A, and since 1990 a combined regimen of
methotrexate and cyclosporine was applied except for
children, who continued to receive cyclosporine alone.
Bone marrow was used as a source of stem cells in 51 of
the 52 transplanted patients and peripheral stem cells in
one. The donor was an HLA-identical sibling in 51 and a
syngeneic donor in one patient.
Data analysis and definitions
A detailed review of all patient charts was the basis of this
report. Variables analyzed included disease-related infor-
mation, treatment (first-line and subsequent), time to
response, time to a first event, and time to death or last
follow-up. Clinical state (transfusions and medication after
first-line treatment) and biological investigations [blood
counts, bone marrow examination, screening tests for
PNH, including hemosiderin in the urine, Ham’s (acid
hemolysin), and sucrose test] were measured before, 3, 6,
and 12 months after first-line treatment, and then annually
until last follow-up.
Response to treatment was defined as follows: complete
remission (CR): neutrophil counts ≥1.5×109 l−1, hemo-
globin ≥120 g/l, and platelet counts ≥150×109 l−1; partial
remission: patients not fulfilling the criteria of CR, but
achieving transfusion independence; nonresponse: patients
who never fulfilled criteria of complete or partial remis-
sion, died from aplasia, or needed a second-line treatment
before fulfilling criteria of partial or complete remission.
An event was defined as nonresponse, relapse of aplastic
anemia, development of a clinically relevant clonal
complication such as MDS, PNH, or solid tumor,
extensive chronic GvHD, or death. Criteria for late clonal
transformation have been published in detail [30]. Labo-
ratory signs of PNH without clinical manifestation, limited
chronic GvHD, and silent nonmalignant tumors (liver
adenomas) were not considered as an event.
Causes of death were subdivided into disease-related
deaths, treatment-related deaths, event-related deaths, and
deaths independent from disease or treatment. Bleeding
and infections were considered disease related as long as
they occurred during the aplastic phase. For ATG patients,
death was treatment related when it occurred during or
immediately after ATG infusion. For transplanted patients,
treatment-related deaths included deaths due to toxicity,
acute GvDH, infections occurring after hemopoietic
regeneration, interstitial pneumonia, and early graft rejec-
tion. Death occurring after relapse, late graft rejection,
MDS, PNH, or solid tumors were classified as event-
related deaths. In all other cases, the cause of death was
classified as not related to aplastic anemia or its treatment.
Statistical analysis
The chi-square test was used for comparisons of
categorical data and the Mann–Whitney U test for
continuous unrelated variables among groups. Survival
probabilities were estimated using the Kaplan–Meier
method [31]. The log-rank test was used to compare
survival [32]. Outcomes analyzed between BMT- and
ATG-treated patients were overall survival, event-free
survival (considering death, extensive chronic GvHD,
secondary malignancy, MDS or clinical PNH, and
nonresponse to treatment or relapse of aplastic anemia as
events), and quality-adjusted survival.
The Q-TWiST is based on subdividing survival times in
distinct successive time lengths of relevant health states.
For comparison of two cancer treatment strategies usually
three states are defined, time with treatment-related
toxicity, time without symptoms and toxicity (TWiST),
and time from treatment failure to death [33, 34]. In
aplastic anemia the situation is more complex. We defined
the following clinically relevant health states (Table 2): the
time in treatment-related toxicity (TOX) was arbitrarily
fixed for patients of both treatment groups and for each
treatment course to 3 months. TWiST was the time an
individual spent in complete remission, free from medi-
cation, and without an event, as described above. The
other relevant health states were time with clonal disease
(CLON), time with extensive chronic GvHD (GvHD),
time with transfusion dependency (TRANS), time with
partial remission (PR), or time with complete remission
but still on medication (CR). A hierarchy of the different
health states was established in case a patient was in two
health states at the same time. Accordingly, time with
CLON stood over all other health states. After that came in
the following order: time with GvHD, time with TRANS,
time with PR, time with CR, and finally time with TWiST.
A utility factor was allocated to each health state varying
on a scale from 0 (as bad as death) to 1 (TWiST) to reflect
the health state’s quality of life value relative to time in
TWiST. The utility coefficient (μ) was defined for TWiST
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as 1, for CR and PR as 0.75, for TOX as 0.25, and for all
other states as 0.5. The weighting of the utility factor was
based on the 30 years of clinical experience of the study
center and was done like the weighting of the original
groups of Q-TWiST. Mean Q-TWiST for each treatment
modality was then calculated from the mean clinical health
state duration as
Q TWiST
¼ TOX  TOX½  þ TWiST½  þ CLON  CLON½ 
þ GvHD  GvHD½  þ TRANS  TRANS½ 
þ PR  PR½  þ CR  CR½ 
where μTOX is the utility coefficient for toxicity, μCLON for
clonal complications, μGvHD for chronic GvHD, μTRANS
for transfusion dependency, μPR for partial remission, and
μCR for complete remission but still with drugs.
A threshold utility analysis comparing BMT with ATG
treatment was performed for PR (UPR), which was the
most relevant health state in terms of duration and
differences between treatment groups. The threshold
utility analysis was calculated for all possible values
ranging from 0.0 to 1.0 (Fig. 2). Finally, Kaplan–Meier
estimates for the time to events that signal transitions
between clinical health states were used to partition the
area under the overall survival curves separately for each
treatment modality [35].
Results
Survival and event-free survival
At the time of last follow-up, 122 of 207 patients [59%;
95% confidence interval (CI) 52–65%] were alive and 85
(41%; 95% CI 34–48%) had died, 24 (46%; 95% CI 32–
62%) after BMT and 61 (39%; 95% CI 32–47%) after
ATG treatment (p=0.241). The probability of survival at
15 years was statistically similar between both treatment
groups; it was 51±15% after transplantation and 53±10%
after ATG (p=0.20), with more early deaths in the
transplant group and more late deaths in the immunosup-
pression group (Fig. 1). There was an improvement in
Table 2 Definitions and criteria of health states for Q-TWiST analysis. MDS myelodysplastic syndrome, PNH paroxysmal nocturnal
hemoglobinuria, GvHD graft-versus-host disease
Name Definition Criteria Utility
coefficient
TWiST Time without symptoms and toxicity
(and without drugs)
Time in complete remission, without drugs, transfusions, clonal disease,
without extended GvHD, and not in toxicity phase
1
TOX Toxicity Initial period of treatment, arbitrarily fixed for each course to 3 months 0.25
TRANS Time with transfusion dependency Time with transfusion dependency, but without clonal disease or extended
GvHD, and not in toxicity phase
0.5
PR Time in partial remission Time not in complete remission, but without transfusion dependency, clonal
disease, or extensive GvHD, and not in toxicity phase
0.75
CR Time in complete remission Time in complete remission, but still receiving drug medication, without
clonal disease, without extended GvHD, and not in toxicity phase
0.75
GvHD Time with extensive GvHD Time with extensive chronic GvHD, but not in toxicity phase 0.5
CLON Time with clonal disease Time with a clonal disease, such as MDS, PNH, or solid tumor 0.5
Fig. 1 a Actuarial survival and event-free survival (EFS) at 15
years according to Kaplan–Meier among 155 patients with aplastic
anemia treated with ATG. b Actuarial survival and event-free
survival (EFS) at 15 years according to Kaplan–Meier among 52
patients with aplastic anemia treated with BMT
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survival probabilities by decade for both treatment groups
with probabilities at 5 years before 1980 of 40±22%
(BMT) and 55±18% (ATG), between 1980 and 1990 of 60
±22% (BMT) and 74±9% (ATG), and after 1990 of 83
±21% (BMT) and 75±18% (ATG). This improvement by
decade was statistically significant for the transplanted
patients (p=0.05), but not for the ATG-treated group
(p=0.1). The event-free survival at 15 years was similar
between both treatment groups (p=0.12), with 25±14%
after BMT and 27±8% after ATG treatment (Fig. 1).
Events and causes of death
Frequency and causes of events and deaths are listed in
Table 3. Fifty-three events were observed in 52 patients
treated with BMT and 196 events in 155 patients treated
with ATG. Of the 52 patients treated with BMT, 21
patients had one and 16 patients two events. Of the 155
patients treated with ATG, 34 patients had one, 39 patients
two, and 23 patients three or more events. During the
study period, 15 of 52 (29%) BMT-treated and 59 of 155
(38%) ATG-treated patients never had an event. The
overall frequency of events was not different between
patients treated with BMT and ATG (p=0.302). However,
there were differences in the type of an event between both
groups. Primary refractory disease occurred significantly
more often after immunosuppression (41 of 196 events,
21% vs 5 of 53 events, 9%, p=0.087), and MDS or
leukemia (21 of 196, 11%, p=0.009) or PNH (18 of 196,
9%, p=0.016) were observed only after immunosuppres-
sion. Extensive chronic GvHD was observed only after
BMT (12 of 53, 23%, p<0.001). There was no difference
in the frequency of relapse/rejection or the occurrence of a
solid tumor between both treatment groups. There were
clear differences in cause of death between both groups
(Table 3). Major cause of death in BMT patients was
treatment related (46%), followed by disease-related
deaths (33%). In contrast, after ATG treatment, the
major cause of death was either disease related (41%) or
event related (41%). Deaths due to toxicity were less
frequent than in BMT patients (Table 3).
Q-TWiST analysis
The mean observation time per patient did not differ
between the treatment groups. It was 6.41 years for
transplanted patients and 7.80 years for ATG-treated
patients (p=0.181). Important differences were found
between both treatment modalities in terms of mean
duration of various health states (Table 4). The mean time
per patient spent with toxicity (ATG 0.36 years, BMT 0.27
years), with transfusion dependency (ATG 0.66 years,
BMT 0.1 years), with partial remission (ATG 3.27 years,
BMT 1.42 years), and with a clonal disorder (ATG 0.68
years, BMT 0.04 years) was significantly longer for ATG-
treated patients compared to patients treated with BMT
(p≤0.001). The difference in time spent with toxicity is
explained by the larger proportion of patients requiring
retreatment in the ATG group. In contrast, patients treated
with BMT spent more time with extensive chronic GvHD
(0.96 years for BMT vs 0 for ATG, p<0.023) and in
TWiST (BMT 2.43 years, ATG 1.22 years, p=0.056).
None of the eight patients receiving ATG as a first-line
treatment developed chronic GvHD after a subsequent
transplant. The time spent in complete remission but still
receiving medication was not statistically different be-
tween both groups, with 1.21 years for BMT and 1.60
years for ATG (p=0.431). Using the utility factors chosen
previously, the Q-TWiST times were similar for the two
treatment groups, i.e., 5.08 years after BMT and 5.72 years
after ATG treatment (Δ−0.64, 95% CI −2.25 to +0.97,
p=0.434). In terms of relative duration, there are
Table 3 Frequency and type of events, as well as causes of deaths







Patients with an event 37 (71%) 96 (62%) 0.302
With a single event 21 (40%) 34 (22%)
With two events 16 (31%) 39 (25%)
With three events 0 (0%) 23 (15%)
Number/type of events 53 196
Primary refractory 5 (9%) 41 (21%) 0.087
Relapse/late rejection 10 (19%) 50 (26%) 0.411
MDS/leukemia 0 (0%) 21 (11%) 0.009
Clinical PNHa 0 (0%) 18 (9%) 0.016
Extensive chronic GvHDb 12 (23%) 0 (0%) <0.001
Malignant tumorc 1 (2%) 5 (2%) 1.0
Death 24 (45%) 61 (31%) 0.077
Others 1 (2%) 0 (0%) 0.213
Number/type of deaths 24 (46%) 61 (39%) 0.241
Treatment-related deaths 11 (46%) 8 (13%) 0.003
Early rejection 3 1d
Acute GvHD 7 0
Toxic 1 7
Disease-related deaths 8 (33%) 25 (41%) 0.686
Bleeding 1 14
Infection 7 11
Event-related deaths 3 (13%) 25 (41%) 0.024
Chronic GvHD 3 0
MDS or leukemia 0 13
PNH 0 2
Relapse of aplastic anemia 0 9
Solid tumor 0 1
Death without evident association 2 (8%) 3 (5%) 0.618
Car accident 1 1
Heart disease 1 1
Unknown 0 1
aBiological paroxysmal nocturnal hemoglobinuria not included
(n=12)
bLocalized cutaneous or mucosal chronic GvHD not included (n=5)
cBenign tumors not included (n=3 liver adenomas)
dAfter secondary bone marrow transplantation
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considerable differences between the health states: BMT
patients spent for instance 38% of their time in TWiST and
19% in PR compared to 16% and 42%, respectively, for
ATG-treated patients (Table 3).
The threshold analysis of the PR utility factor is
presented in Fig. 2. PR is the health state with the largest
difference between the BMT and ATG groups. The plot
illustrates the mean difference in Q-TWiST between BMT
and ATG by varying the UPR between 0 and 1. Irrespective
of utility factor attributed to PR, there is no significant
difference in Q-TWiST among both groups. Figure 3
shows the partitioning of survival times for each treatment
group into the four clinically most relevant health states:
TOX (including time with toxicity and time with transfu-
sion dependency), PR (including time in partial remission
and time in complete remission but requiring drugs),
CLON for ATG group or GvHD for BMT group
(including extensive GvHD and clonal complications),
and TWiST.
Discussion
BMT and immunosuppression are both effective treatment
modalities for patients with aplastic anemia and 15-year
survival probabilities are similar. More early deaths were
observed in the transplant group and more late deaths in
the ATG group. Event-free survival is an outcome measure
that reflects the probability of a patient being alive without
complications due to disease or treatment. This outcome
measure has rarely been used in previous publications of
aplastic anemia [36]. There were no significant differences
in event-free survival at 15 years after BMT and ATG
treatment. However, there were significant differences in
outcomes affecting the quality of life of these patients. The
Q-TWiST analysis allows for a comparison of the time
period spent in different health states when overall
survival does not show a preference between the two
treatment modalities. The quality-adjusted time without
symptoms, toxicity and drugs is similar after BMT and
ATG treatment, but both treatment modalities differ in
Table 4 Quality-adjusted time without symptoms and toxicity (Q-TWiST) and drugs of patients with aplastic anemia treated with bone
marrow transplantation (BMT) or antithymocyte globulin (ATG)
Time interval BMT ATG Δ Between BMT and ATG










95% CI p value
Total years 6.41 333.5 7.80 1,207.5 −1.38 −3.40/+065 0.181
TWiST 2.43 (38%) 126.3 1.22 (16%) 189.3 +0.21 +0.33/+2.45 0.056
TOX 0.27 (4%) 14.3 0.36 (4%) 55.8 −0.09 −0.12/−0.05 <0.001
TRANS 0.10 (1%) 4.8 0.66 (8%) 102.8 −0.57 −0.80/−0.35 <0.001
PR 1.42 (22%) 73.8 3.27 (42%) 507.0 −1.85 −2.93/−0.78 0.001
CR with drugs 1.21 (19%) 63.0 1.60 (20%) 248.3 −0.40 −1.37/+0.59 0.431
GvHD 0.96 (15%) 50.0 0 – +0.96 +0.14/+1.78 0.023
CLON 0.04 (1%) 2.0 0.68 (9%) 104.5 −0.64 −0.88/−0.39 <0.001
Q-TWiSTc 5.08 264.3 5.72 887.2 −0.064 /−2.25/
+0.97
0.434
Fig. 2 Threshold utility analy-
sis was performed for the period
“partial remission” (PR). The
plot of mean difference in Q-
TWiST between BMT- and
ATG-treated patients using a
utility factor (UPR) between 0
and 1 is illustrated. The points
on each side of the line repre-
senting the mean difference in
Q-TWiST are the 95% confi-
dence intervals
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time periods spent in various health states. ATG-treated
patients spent more time requiring transfusions and drugs,
endure longer periods with abnormal blood values, and
have a higher risk of clonal disorder. Patients in the ATG
group required additional treatment more frequently than
BMT patients due to more relapses and a higher incidence
of refractory disease. In contrast, BMT patients spent
nearly 60% of their time without symptoms and toxicity
(in TWiST and CR with drugs).
The implications of these findings must be considered
in the context of benefits of treatment over time. Although
overall survival, event-free survival, or Q-TWiST do not
favor one of the two treatments, BMT patients spent more
time free from any medication and without symptoms of
the disease and toxicity. In contrast, ATG patients spent
more time in health states other than TWiST and therefore
had greater requirements for close medical care, transfu-
sion support, and medication. Our results suggest that
ATG patients spend more time with a reduced quality of
life, and by spending more time in cost-intensive health
states are likely to produce more costs due to medical care.
There is no patient-derived information available to
indicate the appropriate utility factors for health states such
as toxicity, transfusions, clonal disorders, GvHD, or partial
remission. In our view, patients in partial remission have a
fairly good quality of life, restricted by medications and
frequent doctor visits; therefore, the coefficient of 0.75
was chosen for these periods, whereas for periods spent
with transfusion requirements, extensive chronic GvHD,
or clonal complications a coefficient of 0.5 was chosen
reflecting considerable impairment of quality of life. A
coefficient of 0.75 was chosen for the time spent in
complete remission but still requiring regular medication,
because taking drugs on a daily basis clearly interferes
with quality of life. Yet different weighting of the utility
coefficients might affect the results of the Q-TWiST
analysis. Therefore, a threshold utility analysis was
performed for the most relevant health states in terms of
duration and differences between treatment groups. With
this, we show that varying the utility factors for PR does
not affect the results of the Q-TWiST analysis.
There are limitations to this study. Patients receiving
immunosuppression were by study design significantly
older. Therefore, we cannot exclude that age disparity
could play a role in some of the differences observed
between treatment groups. Furthermore, definitions of
transition periods were arbitrary. There is heterogeneity in
some of the transition periods; for instance, the time spent
in partial remission includes patients who have close to
normal blood counts and patients whose hemopoiesis is
just sufficient to keep them free of transfusions. During the
time spent in PR, more transplanted patients have nearly
normal blood values, while ATG patients are more likely
to present lower blood counts. In addition, the study
period covers almost 3 decades. During the whole study
period, changes in the protocols and progress in supportive
care and treatment modalities have led to improvement of
survival and event-free survival. However, there was no
difference in Q-TWiST when comparing ATG-treated
patients and patients treated with BMT (results not shown)
by decade. Finally, Q-TwiST analysis attempts to provide
information on quality of life without direct patient-
centered questionnaires. Such an evaluation is easily
performed in a study covering a limited time period [37].
A Q-TwiST evaluation is much more critical in studies
with chronic disorders, such as aplastic anemia, where the
longest observation time exceeds 20 years and the history
of an individual patient is often complex [37, 38].
Even with these limitations, the Q-TWiST analysis is a
methodology that allows evaluating retrospectively the
time a patient spent at different health states, assuming that
quality of life is dependant on each particular health state
[39], and gives us a complementary view on the outcome
Fig. 3 a Partitioning of survival time for patients treated with ATG
into the four clinically most relevant health states: TOX (including
time with toxicity and time with transfusion dependency), PR
(including time in partial remission and time in complete remission
but necessitating drugs), CLON (including clonal complications),
and TWiST. b Partitioning of survival times for patients treated with
bone marrow transplantation into the four clinically most relevant
health states: TOX (including time with toxicity and time with
transfusion dependency), PR (including time in partial remission
and time in complete remission but necessitating drugs), GvHD
(including extensive GvHD and clonal complications), and TWiST
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of the two standard treatment modalities. Despite similar
survival and event-free survival probabilities, patients
treated with BMT spend more time cured from their
disease, while ATG-treated patients have greater require-
ments for close medical care, transfusion support, and
medications and spend therefore more time in cost-
intensive intervals. The results presented should be helpful
for patient information and making decisions for patients
with aplastic anemia.
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